Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 11/20 | 0.57 |
| ▸ | CHRNA4 | P43681 | 11/20 | 0.57 |
| ▸ | CHRNB4 | P30926 | 7/20 | 0.57 |
| ▸ | CHRNA3 | P32297 | 7/20 | 0.57 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.48 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.48 |
| ▸ | CHRNG | P07510 | 1/20 | 0.48 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.48 |
| ▸ | CHRND | Q07001 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4719579 | 1.00 | CHRNB2 (0.57) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL30116323 | 0.91 | HRH3 (0.57) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL20388854 | 0.91 | HRH3 (0.57) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL29505484 | 0.90 | CHRNB2 (0.55) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL5408335 | 0.90 | CHRNB2 (0.55) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL24746251 | 0.90 | CHRNB2 (0.55) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL29505228 | 0.87 | CHRNB2 (0.62) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL5416037 | 0.87 | CHRNB2 (0.62) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL5405226 | 0.85 | CHRNB2 (0.58) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL22796059 | 0.81 | CHRNB2 (0.52) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221107-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221107-A1 | Therapeutic Agents | HTT, ACHE, GRIN2A | CHRNB2 137/4885CHRNA4 62/4885CHRNB4 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.